Barinthus Biotherapeutics plc completed a merger transaction on September 9, 2026, pursuant to a court-sanctioned scheme of arrangement. Beacon Topco, Inc. acquired all issued and to be issued share capital of Barinthus, making it a wholly-owned subsidiary. Existing shareholders received 0.111 shares of Topco common stock for each ordinary share held. The company's American Depositary Shares were delisted from Nasdaq effective September 9, 2026, and the deposit agreement was terminated. Outstanding equity awards were converted into rights to receive Topco common stock on substantially similar terms. Barinthus Biotherapeutics plc operates in the biotechnology industry, focusing on developing therapies for neurological diseases.

Barinthus Biotherapeutics plc announced that the High Court of Justice of England and Wales sanctioned its Scheme of Arrangement on September 1, 2026. The transaction is now expected to become effective on September 9, 2026, triggering a halt in trading for its American Depositary Shares prior to market open on that date. This update reflects a change from the previously disclosed timeline, while plans for delisting and deregistration remain unchanged. Barinthus Biotherapeutics plc operates as a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.

Barinthus Biotherapeutics plc announced that its Board determined the Scheme Exchange Ratio for its proposed all-stock combination with Clywedog Therapeutics to be 0.111, ensuring Topco's common stock meets Nasdaq's minimum price requirements. The scheme of arrangement is expected to become effective on September 3, 2026, at which point Barinthus Bio will delist its American Depositary Shares from Nasdaq and halt trading prior to the market open. Following the transaction, Topco will be renamed Clywedog Therapeutics Holdings, Inc., with common stock listed under the ticker symbol "CLYD." The company's application for the scheme is scheduled to be heard by a High Court Judge in London on September 1, 2026. Barinthus Biotherapeutics plc operates as a clinical-stage biopharmaceutical company developing immunotherapeutic candidates for autoimmunity and chronic infectious diseases.

Barinthus Biotherapeutics plc reported a net loss of $10.6 million, or $0.26 per share, for the quarter ended June 30, 2026, compared to a $5.5 million loss in the prior quarter. Cash and equivalents decreased to $59.6 million from $67.2 million due to $8.1 million in operating cash usage. The company announced the completion of enrollment for all cohorts in the Phase 1 AVALON trial evaluating VTP-1000 for celiac disease, with topline data expected in Q4 2026. Barinthus Bio also disclosed that Nasdaq granted an extension until December 28, 2026, to regain compliance with listing requirements, resulting in the transfer of its ADSs from the Nasdaq Global Market to the Nasdaq Capital Market effective July 2, 2026. The company is advancing a proposed merger with Clywedog Therapeutics Inc., expected to close in H2 2026. Barinthus Biotherapeutics plc operates as a clinical-stage biopharmaceutical company focused on developing immunotherapeutic drug candidates for autoimmune and inflammatory diseases.

Barinthus Biotherapeutics plc held its 2026 Annual General Meeting on July 2, 2026, where shareholders approved all submitted ordinary resolutions, including the re-election of directors Karen T. Dawes and Anne M. Phillips and the re-appointment of PricewaterhouseCoopers LLP. Additionally, the company received an extension notice from Nasdaq on June 30, 2026, granting an additional 180 days, until December 28, 2026, to regain compliance with the minimum $1.00 bid price requirement. Consequently, the company's American Depositary Shares were transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective July 2, 2026. The company is considering a reverse stock split to resolve the deficiency. Barinthus Biotherapeutics plc is a biotechnology company.